Nesiritide in patients with acute myocardial infarction and heart failure: a meta-analysis
Authors:
Open Access
- 17 January 2020
- journal article
- review article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 48 (1)
Abstract
Objective: This meta-analysis evaluated the efficacy and safety of nesiritide in patients with acute myocardial infarction (AMI) and heart failure. Methods: PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched from inception through December 2018. Studies including patients with AMI and heart failure who received nesiritide were identified. Results: Ten trials involving 870 participants were included in this meta-analysis. Nesiritide treatment significantly increased left ventricular ejection fraction, cardiac index, and 24- and 72-hour urine volumes. Additionally, pulmonary capillary wedge pressure, right atrial pressure, and brain natriuretic peptide and N-terminal brain natriuretic peptide levels were significantly decreased in patients treated with nesiritide compared with those treated with control drugs. However, patients treated with nesiritide did not have an increased risk of mortality compared with those treated with control drugs. There were no differences between the two groups with respect to heart rate or the risk of readmission, hypotension, or renal dysfunction. Conclusions: Nesiritide appears to be safe for patients with AMI and heart failure, and it improves global cardiac and systemic function.Keywords
Funding Information
- National Natural Science Foundation of China (Grant No. 51573211)
This publication has 36 references indexed in Scilit:
- Futility in Cardiology: The Need for a Change in PerspectivesEuropean Journal of Heart Failure, 2019
- Effectiveness and safety of recombinant human brain natriuretic peptide in the treatment of acute myocardial infarctionin elderly in combination with cardiac failurePakistan Journal of Medical Sciences, 2017
- Effect of recombinant human brain natriuretic peptide (rhBNP) versus nitroglycerin in patients with heart failureMedicine, 2016
- Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection FractionCirculation: Heart Failure, 2016
- Effect of rhBNP on renal function in STEMI-HF patients with mild renal insufficiency undergoing primary PCIHeart and Vessels, 2015
- Human recombinant-B-type natriuretic peptide protect ventricular function and structure in ST-elevation myocardial infarction2015
- The annual global economic burden of heart failureInternational Journal of Cardiology, 2014
- B-type natriuretic peptide for prevention of contrast-induced nephropathy in patients with heart failure undergoing primary percutaneous coronary interventionActa Radiologica, 2010
- Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failureThe American Journal of Cardiology, 2004
- Intravenous Nesiritide vs Nitroglycerin for Treatment of Decompensated Congestive Heart FailureJAMA, 2002